MYeloma Resistance And Clonal Evolution

Recruiting Observational Study
Multiple Myeloma
No Placebo Group Every participant receives an active treatment — no one gets a placebo. No Study Drug Researchers observe your health over time — no experimental treatment is given.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Study type
Observational
Participants needed
1,400 (estimated)
Sponsor
Nantes University Hospital · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
Multiple Myeloma (MM) is often associated with progression, temporary response to therapy and a high relapse rate over time resulting in a poor long-term prognosis. Because MM is classified as an incurable disease, therapeutic resistance is of great interest. However, knowledge about the biological mechanisms underlying resistance associated with MM therapies and about associated predictors remain…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Patient consulting due to the discovery or recurrence of MM according to international diagnostic criteria (IMWG 2014) * Patient having consented to participate in the study and his/her biocollection * Patient affiliated to or benefiting from a social security scheme or simila…
Contacts

Cyrille TOUZEAU, PU

02 40 08 32 71

cyrille.touzeau@chu-nantes.fr

CONTACT